United Kingdom · Question · Written question
UIN 9075
Casirivimab/imdevimab
Original
Introduced
25 May 2022
Last action
7 June 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
7 June 2022
Summary
To ask the Secretary of State for Health and Social Care, whether the Government has (a) made an assessment of which groups of immunosuppressed patients should be eligible for treatment with the drug, Ronapreve, as a result of their lack of response to th
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
25 May 2022
Written question
To ask the Secretary of State for Health and Social Care, whether the Government has (a) made an assessment of which groups of immunosuppressed patients should be eligible for treatment with the drug, Ronapreve, as a result of their lack of response to th
Source: Commons
7 June 2022
Answer
While the Medicines and Healthcare products Regulatory Agency has approved Ronapreve for prophylaxis, the treatment has since been found to be ineffective against the Omicron variant and therefore has been withdrawn from general use. There are currently n...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-05-25/9075
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1465757
- uk · wq-1465757 · source updated 7 June 2022